These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 1283893)
1. Castration-like effects on the human prostate of a 5 alpha-reductase inhibitor, finasteride. Geller J; Sionit L J Cell Biochem Suppl; 1992; 16H():109-12. PubMed ID: 1283893 [TBL] [Abstract][Full Text] [Related]
2. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen. Geller J J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965 [TBL] [Abstract][Full Text] [Related]
3. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia. Habib FK; Ross M; Tate R; Chisholm GD Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694 [TBL] [Abstract][Full Text] [Related]
4. The clinical development of a 5 alpha-reductase inhibitor, finasteride. Stoner E J Steroid Biochem Mol Biol; 1990 Nov; 37(3):375-8. PubMed ID: 1701660 [TBL] [Abstract][Full Text] [Related]
5. Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition. Rhodes L; Primka RL; Berman C; Vergult G; Gabriel M; Pierre-Malice M; Gibelin B Prostate; 1993; 22(1):43-51. PubMed ID: 8381228 [TBL] [Abstract][Full Text] [Related]
6. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors. Wu Y; Godoy A; Azzouni F; Wilton JH; Ip C; Mohler JL Prostate; 2013 Sep; 73(13):1470-82. PubMed ID: 23813697 [TBL] [Abstract][Full Text] [Related]
7. Differential effect of 5 alpha-reductase inhibition and castration on androgen-regulated gene expression in rat prostate. Rittmaster RS; Magor KE; Manning AP; Norman RW; Lazier CB Mol Endocrinol; 1991 Jul; 5(7):1023-9. PubMed ID: 1719382 [TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of new specific azasteroid inhibitors of steroid 5 alpha-reductase on canine hyperplastic prostate: suppression of prostatic DHT correlated with prostate regression. Cohen SM; Werrmann JG; Rasmusson GH; Tanaka WK; Malatesta PF; Prahalada S; Jacobs JG; Harris G; Nett TM Prostate; 1995 Feb; 26(2):55-71. PubMed ID: 7531846 [TBL] [Abstract][Full Text] [Related]
9. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. Imperato-McGinley J; Gautier T; Cai LQ; Yee B; Epstein J; Pochi P J Clin Endocrinol Metab; 1993 Feb; 76(2):524-8. PubMed ID: 8381804 [TBL] [Abstract][Full Text] [Related]
10. Effect of castration, DES, flutamide, and the 5 alpha-reductase inhibitor, MK-906, on the growth of the Dunning rat prostatic carcinoma, R-3327. Brooks JR; Berman C; Nguyen H; Prahalada S; Primka RL; Rasmusson GH; Slater EE Prostate; 1991; 18(3):215-27. PubMed ID: 1850515 [TBL] [Abstract][Full Text] [Related]
11. Effects of 5 alpha-reductase inhibitors on intraprostatic androgens in the rat. di Salle E; Giudici D; Biagini L; Cominato C; Briatico G; Panzeri A J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):381-5. PubMed ID: 7626485 [TBL] [Abstract][Full Text] [Related]
12. Finasteride for benign prostatic hyperplasia. Hasinski S; Miller JL; Rose LI Am Fam Physician; 1992 Nov; 46(5):1511-4. PubMed ID: 1279965 [TBL] [Abstract][Full Text] [Related]
13. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Bartsch G; Rittmaster RS; Klocker H World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710 [TBL] [Abstract][Full Text] [Related]
14. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Bartsch G; Rittmaster RS; Klocker H Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of the 5 alpha-reductase inhibitor finasteride and the antiandrogen flutamide on prostate and genital differentiation: dose-response studies. Imperato-McGinley J; Sanchez RS; Spencer JR; Yee B; Vaughan ED Endocrinology; 1992 Sep; 131(3):1149-56. PubMed ID: 1324152 [TBL] [Abstract][Full Text] [Related]
16. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. McConnell JD; Wilson JD; George FW; Geller J; Pappas F; Stoner E J Clin Endocrinol Metab; 1992 Mar; 74(3):505-8. PubMed ID: 1371291 [TBL] [Abstract][Full Text] [Related]
17. The effect of a 5 alpha-reductase inhibitor on androgen physiology in the immature male rat. George FW; Johnson L; Wilson JD Endocrinology; 1989 Nov; 125(5):2434-8. PubMed ID: 2551651 [TBL] [Abstract][Full Text] [Related]
18. [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia]. Bartsch G; Rittmaster RS; Klocker H Urologe A; 2002 Sep; 41(5):412-24. PubMed ID: 12426858 [TBL] [Abstract][Full Text] [Related]
19. Androgen metabolism in the prostate of the finasteride-treated, adult rat: a possible explanation for the differential action of testosterone and 5 alpha-dihydrotestosterone during development of the male urogenital tract. George FW Endocrinology; 1997 Mar; 138(3):871-7. PubMed ID: 9048585 [TBL] [Abstract][Full Text] [Related]
20. C19 and C21 5 beta/5 alpha metabolite ratios in subjects treated with the 5 alpha-reductase inhibitor finasteride: comparison of male pseudohermaphrodites with inherited 5 alpha-reductase deficiency. Imperato-McGinley J; Shackleton C; Orlic S; Stoner E J Clin Endocrinol Metab; 1990 Mar; 70(3):777-82. PubMed ID: 1689740 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]